Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma

This study has been completed.
Information provided by (Responsible Party):
Eisai Inc. Identifier:
First received: December 15, 2006
Last updated: June 30, 2014
Last verified: April 2014